Ginkgo Bioworks Holdings (DNA) Finished Goods (2020 - 2023)
Ginkgo Bioworks Holdings' (DNA) quarterly Finished Goods came in at $4.4 million in Q2 2023, down 41.06% YoY from $7.5 million in Q2 2022, and down 16.26% on a QoQ basis from $5.3 million in Q1 2023.
Analysis
Ginkgo Bioworks Holdings (DNA) Finished Goods (2020 - 2023) Analysis & Trends
Ginkgo Bioworks Holdings (DNA) has 4 years of Finished Goods data on file, last reported at $4.4 million in Q2 2023.
- Quarterly Finished Goods fell 41.06% year-over-year to $4.4 million in Q2 2023, while the trailing twelve-month figure through Jun 2023 was $4.4 million (down 41.06% YoY) and the FY2022 annual result came in at $6.6 million, up 100.86% from the prior year.
- Finished Goods slipped to $4.4 million in Q2 2023, from $5.3 million in the prior quarter.
- In the past five years, Finished Goods ranged from a high of $8.0 million in Q1 2022 to a low of $2.5 million in Q3 2021.
- A 4-year average of $5.1 million and a median of $5.3 million in 2023 frame the typical range for Finished Goods.
- Annual changes were most pronounced in 2022 — Finished Goods soared 120.66% — and 2023, when it tumbled 41.06%.
- Tracing DNA's Finished Goods over 4 years: stood at $2.8 million in 2020, then gained by 18.43% to $3.3 million in 2021, then soared by 100.86% to $6.6 million in 2022, then tumbled by 32.35% to $4.4 million in 2023.
- The last three Finished Goods figures came in at $4.4 million (Q2 2023), $5.3 million (Q1 2023), and $6.6 million (Q4 2022), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.27 Bn | 131.42 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.55 Bn | 77.56 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.45 Bn | 58.27 Bn | 1.37 Bn |
| 4 | Moderna | 57.73 Bn | 52.59 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.14 Bn | 31.84 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn |
| 10 | Ginkgo Bioworks Holdings | 428.45 Mn | 343.92 Mn | 18.44 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2023 | 4.44 Mn |
| Mar 31, 2023 | 5.30 Mn |
| Dec 31, 2022 | 6.56 Mn |
| Sep 30, 2022 | 5.59 Mn |
| Jun 30, 2022 | 7.52 Mn |
| Mar 31, 2022 | 7.98 Mn |
| Dec 31, 2021 | 3.26 Mn |
| Sep 30, 2021 | 2.53 Mn |
| Dec 31, 2020 | 2.76 Mn |